Precision-based Aspirin Chemoprevention

Faculty involved: Yin Cao

In 2016, the U.S. Preventive Services Task Force (USPSTF) released new recommendations supporting the use of low-dose aspirin for the primary prevention of CRC and cardiovascular disease (CVD) in adults aged 50-59 with ≥10% 10-year CVD risk. However, there remain many critical knowledge gaps regarding its mechanisms and effectiveness in preventing other cancers and cancer mortality. Dr. Cao is leading interdisciplinary research to:

  1. Estimate the association between long-term aspirin use and mortality
  2. Refine the current USPSTF guidelines taking into account underlying CRC risk
  3. Assess the impact and challenges in implementation

These efforts will inform future innovative multi-level interventions to improve the implementation of precision aspirin primary prevention strategies across systems, providers, and patients.